Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
about
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitisClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabThe cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.Sclerosing mesenteritis successfully treated with a TNF antagonistUpdate on the treatment of ankylosing spondylitis.Spondyloarthritides: evolving therapiesInfliximab: 12 years of experienceRandomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.Detection of Active Sacroiliitis with Ankylosing Spondylitis through Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging.First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabEarly response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.Infliximab for the treatment of ankylosing spondylitis.Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.TNFalpha blockade in human diseases: an overview of efficacy and safety.Cytokine levels in the serum of healthy subjectsMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesBiologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Infliximab in the treatment of ankylosing spondylitis.Long-term use of adalimumab in the treatment of rheumatic diseases.Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Etanercept: efficacy and safety for approved indications.Biologic agents in inflammatory eye disease.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.The SAPHO syndrome revisited with an emphasis on spinal manifestations.Valuing treatment with infliximab for ankylosing spondylitis using a willingness-to-pay approach.Management of ankylosing spondylitis with infliximab.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.
P2860
Q21195369-921C0B1F-109F-471E-AD04-C8FFB9DC2314Q24816557-A55041C9-D967-4A7D-9B5B-EC8129A772E5Q31142567-F363F1C7-0FDF-4883-B82F-41C4267D9145Q33923298-928317E1-BF60-4198-8117-DC0D03E66C28Q34511356-25214F3D-7354-47D9-83F8-0C653AE0EC00Q34532478-8F2F53BA-832F-4A86-BDD8-BFCA0D4D2345Q34592673-BB86741D-ABBC-4768-B414-00B0A484F2C1Q34613907-BE8A1FEF-861C-4D44-B9FA-3BD7F31CB912Q35070446-838B801D-C79F-419C-87A8-A37AF55FB215Q35535807-F014B767-7621-4386-A677-8AB04EA48CF6Q35554794-5290C193-F9F4-4700-8426-6AA404584C00Q35560343-F189B608-3E11-4ACF-9124-78DD4145EF4BQ35636900-8E49C1A6-E36C-4145-9711-810EDFEB03D9Q35637012-BB2A49CF-3B67-4B21-8930-F59B33731EBCQ35759171-E9796C8C-86D7-4CC5-B4A0-662E1D6DA295Q35896670-C3682E28-9FB4-47A3-9CD2-C23CCE48E52DQ36135031-2FAF903B-F5F0-4E20-BB8A-CFEBB8D29411Q36210882-3551403F-F1B1-48FC-AF52-2269FE7F209FQ36245711-99078FC0-8D65-4980-AFC1-613807E63134Q36365524-694C0652-C8EF-4659-8AAF-A0006CE1D76AQ36458447-2FCF7379-9968-4712-B2D6-ED33ED8E3915Q36536861-54F1B59F-8E2B-4A0A-9649-479A5B1A5906Q36711758-3D2D2426-9BEA-4C56-A911-9F0FC8386429Q36724093-483BC956-C116-4883-A390-7EB2F337BB0CQ36849136-2E8D62EC-0AA1-4956-BCDF-800F29B8BCEBQ37008829-9D645D90-C03A-43E4-AB75-9D1F832765E9Q37172795-7E588304-F334-4C01-BA51-668288EC21B4Q37290474-0625F051-844C-4FDB-8C28-2604571A2F95Q37358124-35E44AC6-42F4-482E-97C3-5B844BAB5D99Q37465416-4FA59220-FA10-4225-9ED4-479864014643Q37690355-2EB5BABF-8845-441B-BEDC-BB8573328BF9Q37729028-F20A96FF-570A-41EF-A72B-BEA1483FC477Q37882064-7DF7B2A4-DB43-447C-BE98-C31416917017Q37954714-32CC14AC-DB94-4415-A060-80C2BFE312B6Q37997772-9472B34E-65FB-4643-9B02-25D380B05CE5Q38246381-1D344AA0-631C-46CA-B980-9BC7852B4ED2Q38261538-EC567D4D-5D3C-4C4A-B91D-519759FD1A05Q38748204-057BCDCA-0416-4EAD-B843-9066043B3667Q38993236-1CC0DBAF-E037-46E9-9602-E70829B00C83Q39085876-B470B7B7-E055-4ADA-A5B4-7AB0583AF3C5
P2860
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Persistent clinical response t ...... sing spondylitis over 3 years.
@en
Persistent clinical response t ...... sing spondylitis over 3 years.
@nl
type
label
Persistent clinical response t ...... sing spondylitis over 3 years.
@en
Persistent clinical response t ...... sing spondylitis over 3 years.
@nl
prefLabel
Persistent clinical response t ...... sing spondylitis over 3 years.
@en
Persistent clinical response t ...... sing spondylitis over 3 years.
@nl
P2093
P2860
P921
P356
P1433
P1476
Persistent clinical response t ...... sing spondylitis over 3 years.
@en
P2093
Baraliakos X
Burmester G
Gromnica-Ihle E
Schneider M
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEH584
P577
2005-03-09T00:00:00Z